Shots:

• The P-III head-to-head ELEVATE-RR trial evaluating Calquence (100mg- PO- bid) vs ibrutinib (420mg- PO- qd) in a ratio (1:1) in 533 patients with previously treated CLL
• The trial met its 1EPs i.e PFS non-inferiority with an m-PFS of 38.4 mos. @median follow up (40.9mos.). The 2EPs include lower incidence of all-grade atrial fibrillation (9.4% vs 16.0%)- safety and tolerability were consistent with the known profile of Calquence- mOS was not reached
• Additionally- P-III ELEVATE-TN trial showed strong PFS benefit of therapy as combination or as monothx. and favorable tolerability through 4 yrs. The results of both trials were presented at ASCO2021

  | Ref: AstraZeneca | Image: Mint